The $13 Million Company Teaching the Immune System to Hunt Cancer

GT Biopharma, Inc. (NASDAQ: GTBP) has disclosed that it currently has three drugs undergoing human trials. The company holds a platform that has been licensed from a leading cancer research university globally. Despite these notable achievements, GT Biopharma's market capitalization is smaller than the value of a Manhattan apartment. This presents a unique opportunity for investors who are willing to explore overlooked areas, as GT Biopharma shows promise in the biopharmaceutical sector.